Another preclinical thumbs-up for Sangamo’s zinc fingers
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
New Pfizer, same problem
Pfizer’s chief executive has pledged to throw money at the pharma giant’s thin pipeline and shirk financial engineering, but only canny deal-making will keep investors on…
Ash 2019 winners and losers
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
Ash 2019 preview – the first winner and losers emerge
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Why Novo Nordisk should buy Uniqure
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
Novo goes early to leapfrog haemophilia gene therapies
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Sigilon Therapeutics approaches the clinic
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
Two more patients bolster Sangamo’s haemophilia A gene therapy
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
PPMD 2019 – Pfizer’s Duchenne gene therapy halt is good news for Sarepta
Worries over toxicity with Pfizer's PF-06939926 halts trial dosing and could leave the way clear for its DMD rival Sarepta.
